12:00 AM
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Deals

Acceleron, Shire deal

Acceleron granted Shire exclusive rights outside North America to its molecules targeting the activin receptor type 2b (ACVR2B) pathway. The deal includes ACE-031, a myostatin...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >